New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
08:41 EDTIMMUImmunomedics reports epratuzumab effects on B-Cell in preclinical study
Immunomedics reported that its lead antibody drug candidate, epratuzumab, has a distinct way of reducing the immune response of B cells, which, in an autoimmune disease such as lupus, are responsible for producing antibodies that attack the patient's own body. Epratuzumab is a humanized antibody targeting the CD22 receptor on B cells. Epratuzumab is being developed in SLE by UCB who hold the worldwide development rights for this compound in autoimmune diseases. Importantly, PBMCs treated with epratuzumab at concentrations ranging from 1 ng/mL to 10 mg/mL produced a U-shaped curve of CD22 with substantial dampening at concentrations lower than 10 ng/mL or greater than 1 mg/mL. These observations may explain why epratuzumab was found in a number of lymphoma and SLE clinical trials to be effective at the mid-doses given and less so at the lower or higher doses. A similar profile was observed for CD19, which was reduced to a similar level over a broad concentration range of epratuzumab.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
10:24 EDTIMMUHigh option volume stocks
High option volume stocks: TIVO TIF ASHR OCR TGP JEC CEQP UTX PWRD IMMU
November 21, 2014
08:35 EDTIMMUImmunomedics granted FDA orphan drug designation for veltuzumab
Immunomedics announced that the Office of Orphan Products Development of the FDA has granted orphan status for the use of veltuzumab, the company's humanized anti-CD20 antibody, for the treatment of pemphigus. Pemphigus is a debilitating and potentially fatal autoimmune blistering disease of the skin and mucous membranes. In most cases, irregularly-shaped, painful erosions or lesions initially develop in the mucous membranes lining the inside of the mouth. To maintain disease control typically requires long-term exposure to corticosteroids and other drugs which suppress the immune system and may themselves contribute to osteoporosis, septicemia, and other serious adverse events seen in this population.
November 20, 2014
08:37 EDTIMMUImmunomedics says partial response achieved for 11 months in IMMU-130 trial
Subscribe for More Information
November 18, 2014
17:09 EDTIMMUImmunomedics veltuzumab designated for orphan status
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use